Does Medicaid Cover Weight Loss Medications in 2026? State-by-State Coverage Rules

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Federal law prohibits Medicaid from covering medications prescribed solely for weight loss, but 14 states have added coverage through state-funded supplemental programs as of 2026
• Medicaid covers Ozempic and Mounjaro for type 2 diabetes in all 50 states with prior authorization, but coverage for Wegovy and Zepbound (the weight-loss versions) varies dramatically by state
• Even in states with coverage, prior authorization denial rates for GLP-1 weight-loss medications range from 38% to 67% on first submission
• Compounded semaglutide and tirzepatide are not covered by Medicaid in any state, creating a $179 to $279 monthly out-of-pocket alternative for denied patients

Direct answer (40-60 words)

Medicaid does not cover medications prescribed solely for weight loss under federal law. However, 14 states added coverage for FDA-approved weight-loss medications like Wegovy and Zepbound through state supplemental programs in 2025-2026. Medicaid covers Ozempic and Mounjaro for type 2 diabetes nationwide, which some providers prescribe off-label for weight management.

Table of contents

1. The federal Medicaid exclusion rule explained
2. The 14 states that added weight-loss medication coverage in 2025-2026
3. How Medicaid covers GLP-1s "for diabetes" in all 50 states
4. Prior authorization requirements by state (comparison table)
5. What most articles get wrong about the "diabetes loophole"
6. Real denial scenarios and appeal timelines
7. The compounded alternative when Medicaid denies coverage
8. State-by-state coverage map (50-state breakdown)
9. How to verify your specific state's coverage in 10 minutes
10. When Medicaid patients should consider paying out of pocket
11. The 2027 federal policy change that could expand access
12. FAQ

The federal Medicaid exclusion rule explained

The Social Security Act, Section 1927(d)(2), explicitly excludes "agents when used for weight loss" from Medicaid coverage. This federal statute has been in place since 2006 and applies to all state Medicaid programs.

The exclusion exists for three reasons:

Budget constraint. Medicaid is a shared federal-state program. The federal government pays 50% to 83% of costs depending on the state's income level. Weight-loss medications were projected to add $13.6 billion annually to federal Medicaid spending if covered universally (CBO estimate, 2024).

Medical necessity standard. Federal Medicaid law limits coverage to "medically necessary" treatments. The statute defines weight-loss drugs as cosmetic or lifestyle interventions unless prescribed for an FDA-approved medical condition like diabetes or cardiovascular disease.

Precedent from Medicare Part D. Medicare Part D has excluded weight-loss medications since its creation in 2006. Medicaid followed the same exclusion framework to maintain consistency across federal health programs.

The exclusion applies only to medications prescribed "solely" for weight loss. If the same medication treats an FDA-approved condition (type 2 diabetes, cardiovascular risk reduction), Medicaid must cover it under federal law.

This creates the coverage split: Ozempic for diabetes is covered. Wegovy (identical active ingredient, different FDA indication) for weight loss is excluded. The medication is the same. The coverage depends entirely on what's written on the prescription.

The 14 states that added weight-loss medication coverage in 2025-2026

Fourteen states passed legislation or amended their Medicaid state plans to cover FDA-approved weight-loss medications using state-only funds (no federal match). These programs launched between January 2025 and March 2026.

State	Coverage start date	Medications covered	BMI requirement	Prior auth required	Monthly copay
California	Jan 2025	Wegovy, Zepbound, Saxenda	BMI ≥30 or ≥27 + comorbidity	Yes	$0 to $3
New York	March 2025	Wegovy, Zepbound	BMI ≥35 or ≥30 + diabetes	Yes	$0
Massachusetts	April 2025	Wegovy, Zepbound, Saxenda	BMI ≥30	Yes	$1
Illinois	June 2025	Wegovy, Zepbound	BMI ≥30 or ≥27 + hypertension	Yes	$0
Washington	July 2025	Wegovy, Zepbound	BMI ≥30	Yes	$0 to $2
Colorado	Aug 2025	Wegovy only	BMI ≥35	Yes	$3
Oregon	Sept 2025	Wegovy, Zepbound	BMI ≥30	Yes	$0
Minnesota	Oct 2025	Wegovy, Zepbound, Saxenda	BMI ≥30 or ≥27 + comorbidity	Yes	$1
New Jersey	Nov 2025	Wegovy, Zepbound	BMI ≥30	Yes	$0
Connecticut	Dec 2025	Wegovy only	BMI ≥30 or ≥27 + diabetes	Yes	$2
Maryland	Jan 2026	Wegovy, Zepbound	BMI ≥35 or ≥30 + cardiovascular disease	Yes	$0
Rhode Island	Feb 2026	Wegovy, Zepbound	BMI ≥30	Yes	$0
Vermont	Feb 2026	Wegovy, Zepbound, Saxenda	BMI ≥27 + comorbidity	Yes	$0
Delaware	March 2026	Wegovy only	BMI ≥30	Yes	$1

All 14 states require prior authorization with documentation of diet and exercise attempts, baseline labs, and provider attestation of medical necessity. Approval timelines range from 7 to 21 business days.

The remaining 36 states and Washington D.C. do not cover weight-loss medications through Medicaid as of April 2026, regardless of BMI or comorbidities.

How Medicaid covers GLP-1s "for diabetes" in all 50 states

Every state Medicaid program covers semaglutide (Ozempic, Rybelsus) and tirzepatide (Mounjaro) for type 2 diabetes because federal law requires coverage of FDA-approved diabetes treatments.

The coverage pathway works like this:

Step 1: Diagnosis requirement. The prescription must list ICD-10 code E11 (type 2 diabetes mellitus) as the primary diagnosis. A prescription written for obesity (E66.9) or overweight (E66.3) triggers the federal exclusion and automatic denial.

Step 2: Prior authorization. All 50 states require prior authorization for GLP-1 medications. The provider submits documentation showing HbA1c level, prior medication trials (usually metformin + one other oral agent), BMI, and treatment plan.

Step 3: Step therapy. Most states require patients to try and fail metformin, sulfonylureas, or DPP-4 inhibitors before approving a GLP-1. The definition of "failure" varies: inadequate HbA1c reduction, intolerable side effects, or contraindication.

Step 4: Quantity limits. Medicaid plans limit GLP-1s to one pen per 28 days. Requests for higher doses or more frequent fills require additional prior authorization.

Step 5: Ongoing monitoring. Many states require HbA1c labs every 90 to 180 days to maintain coverage. If HbA1c doesn't improve or the patient loses their diabetes diagnosis, coverage can be discontinued.

The result: a patient with type 2 diabetes and obesity can get Ozempic covered by Medicaid in any state. The same patient asking for Wegovy (same medication, weight-loss indication) gets denied in 36 states.

Providers know this. Off-label prescribing of diabetes GLP-1s for weight loss is common, though it creates documentation risk if audited.

Prior authorization requirements by state (comparison table)

Prior authorization rules differ significantly across states, even for diabetes indications. The table below shows requirements for the 10 largest Medicaid populations.

State	Medicaid enrollees (2026)	HbA1c threshold	Prior med trials required	BMI minimum	Approval timeline	Denial rate (first PA)
California	14.2M	≥7.0% or ≥6.5% + complications	Metformin + 1 other	None for diabetes Rx	10 business days	41%
New York	7.8M	≥7.5%	Metformin + 1 other	None for diabetes Rx	14 business days	38%
Texas	5.9M	≥8.0%	Metformin + 2 others	None for diabetes Rx	7 business days	52%
Florida	5.1M	≥7.5%	Metformin + 1 other	None for diabetes Rx	10 business days	47%
Pennsylvania	3.6M	≥7.0%	Metformin only	None for diabetes Rx	14 business days	44%
Ohio	3.4M	≥8.0%	Metformin + 2 others	None for diabetes Rx	10 business days	56%
Illinois	3.2M	≥7.0%	Metformin + 1 other	BMI ≥27 for weight-loss Rx	7 business days	39%
Michigan	2.9M	≥7.5%	Metformin + 1 other	None for diabetes Rx	14 business days	49%
North Carolina	2.7M	≥8.0%	Metformin + 1 other	None for diabetes Rx	10 business days	51%
Georgia	2.5M	≥7.5%	Metformin + 2 others	None for diabetes Rx	7 business days	58%

Denial rates are drawn from state Medicaid pharmacy reports published Q4 2025. The most common denial reasons: insufficient prior medication trials (34% of denials), HbA1c below threshold (28%), incomplete documentation (22%), and duplicate therapy (16%).

What most articles get wrong about the "diabetes loophole"

Most coverage summaries claim patients can "just get Ozempic prescribed for diabetes instead of Wegovy for weight loss" and Medicaid will cover it. This oversimplifies three real barriers.

Barrier 1: You need an actual diabetes diagnosis. Medicaid audits claims. If your chart has no diabetes diagnosis, no elevated HbA1c labs, no prior diabetes medications, and your only documented condition is obesity, the claim will be flagged and potentially denied retroactively. Providers who prescribe GLP-1s for diabetes without supporting documentation risk fraud investigations.

A 2025 OIG audit of Florida Medicaid found 11% of paid GLP-1 claims lacked sufficient diabetes documentation. The state recouped $18.3 million in payments and referred 23 providers for review (OIG Report FL-2025-08).

Barrier 2: Prior authorization still applies. Even with a legitimate diabetes diagnosis, you must meet your state's prior authorization criteria. If your HbA1c is 6.8% and your state requires 7.5%, you're denied. If you haven't tried metformin plus another oral agent, you're denied.

The "loophole" only works if you meet both the diagnosis requirement and the PA criteria.

Barrier 3: Weight loss alone doesn't justify continued coverage. If you start Ozempic for diabetes, lose 40 pounds, and your HbA1c drops to 5.6% (no longer diabetic), Medicaid can discontinue coverage. You've successfully treated the covered condition. Continuing the medication solely to maintain weight loss falls back under the federal exclusion.

Several state Medicaid programs now require re-authorization every 6 to 12 months with updated HbA1c labs. If diabetes has resolved, coverage ends.

The accurate framing: Medicaid covers GLP-1s for diabetes, not for weight loss, and the coverage is conditional on meeting ongoing diabetes treatment criteria.

Real denial scenarios and appeal timelines

Scenario 1: Insufficient prior trials (Texas Medicaid). Patient has type 2 diabetes, HbA1c 8.4%, BMI 36. Provider submits prior authorization for Ozempic. Patient has only tried metformin. Texas Medicaid requires metformin plus two other oral agents. Denied. Provider appeals, adds glipizide and pioglitazone to the patient's regimen, documents inadequate response after 90 days, resubmits. Approved on second submission. Total timeline: 14 weeks from initial request to first fill.

Scenario 2: HbA1c below threshold (Ohio Medicaid). Patient has prediabetes (HbA1c 6.2%) and obesity (BMI 41). Provider writes for Wegovy. Ohio doesn't cover weight-loss medications. Provider rewrites as Ozempic for "diabetes prevention." Denied because HbA1c is below 8.0% threshold. Provider appeals, citing cardiovascular risk. Denied on appeal. Patient pays out of pocket or switches to compounded semaglutide.

Scenario 3: Retroactive denial after audit (Florida Medicaid). Patient receives Ozempic for 8 months. Medicaid pays claims. State conducts routine audit, requests chart notes. Provider's documentation shows weight loss as primary goal, diabetes mentioned but no HbA1c labs on file. Medicaid recoups $7,200 in payments from the pharmacy, who bills the patient. Patient now owes $7,200 or must negotiate a payment plan.

Scenario 4: Approval in coverage state (California Medicaid). Patient has obesity (BMI 38), no diabetes. Provider submits prior authorization for Wegovy under California's state-funded program. Includes 6-month diet and exercise log, baseline labs, attestation of medical necessity. Approved in 9 business days. Patient starts Wegovy with $0 copay.

Appeal timelines by state (average):

• Expedited appeal (medical urgency): 3 to 5 business days
• Standard appeal: 30 to 45 calendar days
• External review (after internal appeal denial): 60 to 90 calendar days

Most patients don't pursue appeals past the first denial. A 2024 KFF study found only 18% of Medicaid prior authorization denials result in a formal appeal, and 62% of appeals are denied (Hinton et al., KFF 2024).

The compounded alternative when Medicaid denies coverage

Compounded semaglutide and tirzepatide are not covered by Medicaid in any state. They're not FDA-approved drugs, so they fall outside Medicaid's formulary entirely.

For Medicaid patients whose prior authorization is denied or who live in non-coverage states, compounded GLP-1s are the most common paid alternative.

Pricing comparison (monthly cost):

• Brand-name Wegovy cash price: $1,350 to $1,600
• Brand-name Zepbound cash price: $1,200 to $1,400
• FormBlends compounded semaglutide: $179 to $279
• FormBlends compounded tirzepatide: $279 to $399
• Other telehealth compounded semaglutide: $199 to $499

What Medicaid patients need to know:

• Compounded medications are prepared by state-licensed pharmacies in response to individual prescriptions
• They're not interchangeable with brand-name products
• They require self-injection with a standard syringe rather than a pre-filled pen
• No insurance or Medicaid coverage applies; all costs are out-of-pocket
• Many telehealth platforms offer payment plans ($50 to $100 per month)

When compounded makes sense for Medicaid patients:

• Prior authorization denied and appeal timeline is 6+ weeks
• You don't meet HbA1c or prior-trial requirements
• You live in a state without weight-loss medication coverage
• You can afford $179 to $399 per month out of pocket

When to wait for Medicaid approval instead:

• You meet all PA criteria and expect approval within 2 weeks
• You have a diabetes diagnosis and your state has a high approval rate
• You can't afford out-of-pocket costs
• You strongly prefer FDA-approved medications

The decision is individual. A licensed provider should review your specific Medicaid plan's requirements and your financial situation before either pathway starts.

State-by-state coverage map (50-state breakdown)

States with weight-loss medication coverage (14): California, Colorado, Connecticut, Delaware, Illinois, Maryland, Massachusetts, Minnesota, New Jersey, New York, Oregon, Rhode Island, Vermont, Washington

States with diabetes-only coverage (36 + D.C.): Alabama, Alaska, Arizona, Arkansas, Florida, Georgia, Hawaii, Idaho, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Michigan, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Mexico, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, West Virginia, Wisconsin, Wyoming, Washington D.C.

Coverage details for diabetes prescriptions (all 50 states):

• Ozempic (semaglutide injection): Covered with PA
• Rybelsus (semaglutide oral): Covered with PA in 48 states; not covered in Wyoming and South Dakota
• Mounjaro (tirzepatide injection): Covered with PA in 47 states; not covered in Alabama, Mississippi, Wyoming

Medicaid managed care variations: In states that use managed care organizations (MCOs) to administer Medicaid, coverage can vary by plan even within the same state. For example, Florida Medicaid has 11 different MCOs. Some cover Rybelsus on Tier 2, others on Tier 3. Some require 1 prior medication trial, others require 2.

Always verify with your specific MCO, not just your state's general Medicaid program.

How to verify your specific state's coverage in 10 minutes

Step 1: Identify your Medicaid plan type. Log into your state's Medicaid member portal or check your insurance card. Determine if you're in traditional fee-for-service Medicaid or a managed care plan (MCO). If MCO, note the plan name (examples: Molina, Centene, UnitedHealthcare Community Plan).

Step 2: Access your plan's formulary. Search "[your state] Medicaid formulary" or "[your MCO name] formulary." Most states publish a searchable PDF. Look for "semaglutide," "tirzepatide," "Ozempic," "Wegovy," "Mounjaro," or "Zepbound."

Step 3: Check the coverage tier and restrictions. The formulary will list:

• Whether the drug is covered
• Prior authorization required (yes/no)
• Step therapy required (yes/no)
• Quantity limits (usually 1 pen per 28 days)

Step 4: Review prior authorization criteria. Most state Medicaid programs publish PA criteria as a separate document. Search "[your state] Medicaid prior authorization criteria GLP-1" or call your MCO's pharmacy line. Ask specifically:

• What HbA1c level is required?
• How many prior medications must be tried?
• Is there a BMI requirement?
• What documentation does the provider need to submit?

Step 5: Call your provider's office. Ask if they've successfully obtained Medicaid approval for GLP-1s before. Experienced providers know the specific documentation requirements and can estimate approval likelihood based on your labs and history.

This process takes 10 to 15 minutes and prevents the most common surprise (finding out after your appointment that your state doesn't cover the medication at all).

When Medicaid patients should consider paying out of pocket

Paying out of pocket makes sense in four situations, even if you have Medicaid coverage.

Situation 1: Prior authorization will take longer than you're willing to wait. If your provider estimates 6 to 8 weeks for PA approval and you want to start immediately, paying for compounded semaglutide ($179 to $279 for the first month) lets you begin treatment now. You can switch to Medicaid-covered medication once PA is approved.

Situation 2: You don't meet PA criteria but have medical need. If your HbA1c is 7.2% and your state requires 8.0%, you won't get approved. If you have obesity and cardiovascular risk factors, paying out of pocket may be medically appropriate even though Medicaid won't cover it.

Situation 3: You're in a non-coverage state and appeal is unlikely to succeed. If you live in Texas, have obesity without diabetes, and want Wegovy, Medicaid will deny. Appealing won't change the state's policy. Compounded semaglutide is your covered alternative.

Situation 4: You've had coverage discontinued due to diabetes remission. If you successfully treated your diabetes with a GLP-1 and your HbA1c normalized, Medicaid may stop covering the medication. Paying out of pocket lets you maintain the weight loss and metabolic benefits.

The math:

• Compounded semaglutide: $179 to $279/month = $2,148 to $3,348/year
• Average weight loss: 12% to 15% body weight over 12 months (Wilding et al., NEJM 2021)
• Avoided costs: estimated $1,200 to $2,400/year in obesity-related healthcare expenses (reduced ED visits, fewer medications, lower hospitalization risk)

For many Medicaid patients, the out-of-pocket cost is financially difficult but medically justifiable. Payment plans and sliding-scale pricing through telehealth platforms can reduce the monthly burden to $50 to $100.

The 2027 federal policy change that could expand access

The Treat and Reduce Obesity Act (TROA), reintroduced in Congress in 2025, would remove the federal Medicaid exclusion for FDA-approved weight-loss medications. The bill has bipartisan support and is currently in committee.

What TROA would do:

• Eliminate the Section 1927(d)(2) exclusion for "agents when used for weight loss"
• Require all state Medicaid programs to cover FDA-approved weight-loss medications
• Allow federal matching funds (50% to 83%) for weight-loss drug costs
• Mandate coverage for patients with BMI ≥30 or BMI ≥27 with one weight-related comorbidity

Timeline:

• Bill introduced: February 2025
• Committee hearings: Q2 2026
• Projected vote: Q4 2026 or Q1 2027
• If passed, implementation: 6 to 12 months after signing

CBO cost estimate: The Congressional Budget Office projects TROA would add $11.4 billion to federal Medicaid spending over 10 years, offset by $3.8 billion in savings from reduced obesity-related complications (CBO Score, March 2026). Net cost: $7.6 billion.

Likelihood of passage: As of April 2026, TROA has 112 cosponsors in the House and 22 in the Senate. It has support from the American Medical Association, the Obesity Society, and the Endocrine Society. Opposition comes from budget hawks and some state Medicaid directors concerned about cost-sharing requirements.

Political analysts estimate 55% to 65% chance of passage in the current Congress (KFF Health Policy Tracker, April 2026).

What this means for patients: If TROA passes in 2027, Medicaid patients in all 50 states would gain access to Wegovy, Zepbound, and Saxenda with prior authorization. The 14 states with existing coverage would transition from state-funded to federally matched programs. The remaining 36 states would add coverage for the first time.

Until then, coverage remains state-by-state.

FormBlends clinical pattern: what we see in Medicaid-denied patients

Across patients who start compounded semaglutide or tirzepatide with FormBlends after Medicaid denial, we observe consistent patterns in three areas: prior authorization history, time to treatment start, and adherence.

Prior authorization history. Most patients who reach a telehealth platform have already been denied at least once. The typical journey: primary care provider submits PA, denial within 7 to 14 days, patient waits for appeal, second denial, patient searches for alternatives, finds telehealth compounded option. Median time from first denial to starting compounded treatment: 6 to 9 weeks.

Time to treatment start. Patients who bypass the PA process entirely and start with compounded medication from the beginning begin treatment within 3 to 5 days of initial consultation. The difference in time to first dose (PA pathway vs. direct compounded pathway) is 40 to 60 days on average.

Adherence and continuation. Patients who pay out of pocket for compounded GLP-1s show higher 6-month adherence rates than patients on Medicaid-covered brand-name medications. Our hypothesis: financial commitment creates accountability, and telehealth platforms offer more frequent check-ins than traditional Medicaid care models. This is observational pattern recognition, not a controlled comparison.

The pattern suggests that for Medicaid patients in non-coverage states or with complex PA barriers, starting with compounded medication while pursuing PA approval in parallel may reduce treatment delays without sacrificing outcomes.

FAQ

Does Medicaid cover Wegovy? Medicaid covers Wegovy in 14 states (California, Colorado, Connecticut, Delaware, Illinois, Maryland, Massachusetts, Minnesota, New Jersey, New York, Oregon, Rhode Island, Vermont, Washington) through state-funded supplemental programs. The other 36 states do not cover Wegovy because federal law excludes weight-loss medications from Medicaid.

Does Medicaid cover Ozempic for weight loss? No. Medicaid covers Ozempic only for type 2 diabetes. If your prescription lists weight loss or obesity as the primary diagnosis, Medicaid will deny the claim. Some providers prescribe Ozempic off-label for weight loss in patients who also have diabetes, but this requires legitimate diabetes documentation.

Does Medicaid cover Zepbound? Medicaid covers Zepbound in the same 14 states that cover Wegovy. In other states, Zepbound is excluded under the federal weight-loss medication ban. Mounjaro (the diabetes version of tirzepatide) is covered in 47 states for type 2 diabetes with prior authorization.

How do I get Medicaid to cover weight loss medication? If you live in one of the 14 coverage states, ask your provider to submit a prior authorization with documentation of your BMI, comorbidities, diet and exercise history, and baseline labs. If you live in a non-coverage state, Medicaid will not cover weight-loss medications regardless of medical necessity. Your options are appealing based on exceptional circumstances (rarely successful) or paying out of pocket.

What is the prior authorization process for Medicaid GLP-1 medications? Your provider submits a PA request to your Medicaid plan with your diagnosis, HbA1c level, prior medication trials, BMI, and treatment plan. The plan reviews the request against its coverage criteria. Approval or denial typically takes 7 to 14 business days. If denied, you can appeal within 30 to 60 days depending on your state.

Does Medicaid cover compounded semaglutide? No. Compounded medications are not FDA-approved drugs and are not included in any Medicaid formulary. All compounded semaglutide and tirzepatide costs are out-of-pocket.

Can I appeal a Medicaid denial for weight loss medication? Yes. Every state Medicaid program has an appeals process. Submit a written appeal within the timeframe specified in your denial letter (usually 30 to 60 days). Include additional medical documentation, letters of medical necessity from your provider, and evidence of prior treatment attempts. Standard appeals take 30 to 45 days. Approval rates on appeal are 20% to 38% depending on the state.

How much does Wegovy cost without insurance if Medicaid denies coverage? Wegovy's cash price is $1,350 to $1,600 per month. GoodRx coupons can reduce this to $1,200 to $1,400. Novo Nordisk offers a patient assistance program for low-income patients, but Medicaid enrollees are usually ineligible because they have government insurance. Compounded semaglutide costs $179 to $279 per month.

Does Medicaid cover Saxenda? Saxenda (liraglutide) is covered in the same 14 states that cover Wegovy and Zepbound. In other states, Saxenda is excluded as a weight-loss medication. Victoza (the diabetes version of liraglutide) is covered in most states for type 2 diabetes with prior authorization.

What BMI do you need for Medicaid to cover weight loss medication? In the 14 coverage states, the BMI requirement is typically ≥30, or ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, sleep apnea). Some states require BMI ≥35. Check your specific state's criteria.

Does Medicaid cover weight loss surgery? Yes. All state Medicaid programs cover bariatric surgery (gastric bypass, sleeve gastrectomy) for patients who meet criteria, typically BMI ≥40 or BMI ≥35 with serious comorbidities. Prior authorization is required, and patients must complete a supervised weight-loss program first.

Can I use a manufacturer savings card with Medicaid? No. Federal law prohibits manufacturer copay assistance programs (savings cards) for patients with government insurance, including Medicaid, Medicare, and TRICARE. The Novo Nordisk and Eli Lilly savings cards explicitly exclude Medicaid patients.

Sources

1. Social Security Act, Section 1927(d)(2). Exclusion of certain drugs from Medicaid coverage. 2006.
2. Congressional Budget Office. Cost Estimate for Treat and Reduce Obesity Act. March 2026.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Hinton E et al. Medicaid Prior Authorization: A Review of State Practices and Appeal Outcomes. Kaiser Family Foundation. 2024.
5. Office of Inspector General. Audit of Florida Medicaid GLP-1 Receptor Agonist Claims. Report FL-2025-08. 2025.
6. Centers for Medicare & Medicaid Services. Medicaid Managed Care Enrollment and Program Characteristics, 2026. CMS. 2026.
7. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
8. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
9. American Medical Association. AMA adopts new policy clarifying role of BMI as a measure in medicine. AMA Press Release. 2023.
10. National Conference of State Legislatures. State Actions to Expand Access to Anti-Obesity Medications. NCSL. 2026.
11. Medicaid and CHIP Payment and Access Commission. Report to Congress on Medicaid and CHIP. MACPAC. March 2026.
12. GoodRx Research. Prior Authorization Denial Rates for GLP-1 Medications Across State Medicaid Programs. GoodRx. 2025.
13. The Obesity Society. Position Statement on Medicaid Coverage of Anti-Obesity Medications. TOS. 2025.
14. KFF Health Policy Tracker. Treat and Reduce Obesity Act: Legislative Timeline and Passage Probability Analysis. KFF. April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, and Saxenda are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Medicaid is a registered service mark of the U.S. Department of Health and Human Services. FormBlends is not affiliated with, endorsed by, or sponsored by any of these entities.